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t has been more than a century since coccidioidomycosis 
was ﬁ  rst recognized as a serious disease, and its etiology 
and epidemiology have been well documented. But 
the disease remains an enigma to many, and it often goes 
undiagnosed, even in endemic areas. As management of 
this chronic disease remains problematic, new preventive or 
therapeutic options are needed.
Etiology and Epidemiology
Coccidioidomycosis is a fungal disease found only in the 
Western Hemisphere. It is caused by two nearly identical 
species, Coccidioides immitis and C. posadasii, generically 
referred to as the “Californian” and “non-Californian” species 
respectively [1]. The fungus grows in a mycelial phase (see 
Box 1) in the soil within a geographically delineated area of 
the United States known as the Lower Sonoran Life Zone [2]. 
This semiarid zone encompasses the southern parts of Texas, 
Arizona, New Mexico, and much of central and southern 
California (Figure 1). 
Endemic regions for coccidioidomycosis have long been 
identiﬁ  ed in semiarid areas in Mexico [3], and smaller 
endemic foci have been described in areas of Central and 
South America [4,5]. More recently, Brazil has also been 
found to contain endemic areas in the semiarid northeastern 
states of the country [6]. The climatic conditions and ﬂ  ora of 
these states are similar to those in endemic regions in North, 
Central, and South America. In Latin America, Mexico has 
the largest number of reported cases, with the prevalence 
of infection in northern Mexico reported to be between 
10%–40% [7,8]. C. posadasii is thought to be the predominant 
species in Mexico [3]. 
As the soil dries or nutrients become limiting, the fungus 
reproduces asexually by disarticulating the hyphae into 
small, environmentally-resistant arthroconidia (reproductive 
spores) (Figure 2). These are easily aerosolized when the 
soil is disturbed by wind or human activities. Consequently, 
it is the inhalation of the dust-borne arthroconidia that leads 
to infection by this pathogenic fungus in both humans and 
domestic or wild mammals. Upon inhalation, the fungus 
converts to a unique life cycle of alternating spherules 
and progeny endospores, which comprises the parasitic 
phase of this dimorphic fungus (Figure 2) [9]. Mycelial 
elements are only occasionally found in diseased tissue [10]. 
Coccidioidomycosis is not contagious; reports of human-to-
human spread are extremely rare. Hence, primary exposure 
to contaminated dust is the sole risk factor for the acquisition 
of this disease.
It is estimated that upwards of 100,000 primary coccidioidal 
infections occur in humans each year in the endemic areas 
of the United States [11]. In recent years, the incidence of 
the disease has increased in California and Arizona , which 
may be partially due to the rapid immigration of previously 
unexposed persons from states outside the endemic areas (in 
other words, the pool of susceptible people has increased) 
[12]. In the United States, diagnosis in patients who have 
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Figure 1. Geographic Distribution of Coccidioidomycosis
(Illustration: Margaret Shear)
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symptoms is established by serodiagnosis in conjunction 
with patient history. In previous decades, a coccidioidal 
skin test antigen was a useful adjunct in the diagnosis, but 
it became unavailable in the 1980s [13]. The incidence of 
primary pulmonary disease outside the United States is not 
established; most reports are limited to disseminated or 
unusual cases [14]. Diagnosis in Latin America is usually 
based on microbiologic ﬁ  ndings, as serology is not always 
available [14].
Clinical Features
In their pioneering epidemiologic studies, Smith and 
colleagues found that about 60% of exposures to the 
fungus result in asymptomatic infection [15]. In the 40% of 
patients who have symptomatic disease, there are protean 
manifestations. These range from a primary, or benign, 
pulmonary infection (commonly known as “Valley Fever”) to 
a progressive pulmonary or extrapulmonary disease involving 
the skin, bones and/or joints, the central nervous system, and 
other organ systems. Fortunately, most patients with primary 
disease recover spontaneously and retain lifelong immunity 
to exogenous reinfection. Chronic and disseminated disease 
is estimated to occur in up to 5% of infected individuals, 
with comparatively more cases occurring in older individuals 
and in males [12]. The most dangerous form of the disease 
is meningeal infection, which occurs in about 0.15%–0.75% 
of extrapulmonary coccidioidomycosis cases and requires 
treatment for life [16].
In regions where tuberculosis rates are high, the 
two diseases may occur together. Tuberculosis and 
coccidioidomycosis share common epidemiological, clinical, 
radiographic, and even histopathological features, making 
a correct diagnosis extremely difﬁ  cult in cases where both 
diseases coexist. In areas where both diseases are endemic, 
the pertinent studies for diagnosing both conditions should 
be performed in every patient with compatible clinical 
features. The diagnosis of one of them does not exclude the 
possible existence of the other [17].
Treatment
Historically, patients with the primary respiratory form of the 
disease were not treated because the vast majority recovered 
on their own. Instead, such patients were given supportive 
care and were monitored, often with radiographs, until the 
disease resolved. In recent years, however, an increasing 
number of physicians are prescribing azole antifungals in 
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Figure 2. Life Cycle of Coccidioides immitis 
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cases of primary disease, both because drugs like ﬂ  uconazole 
have a good safety record, and because there is a perception 
that treatment may prevent progression to more serious 
forms of the disease. This latter presumption, however, is not 
supported by controlled trial data.
All cases of chronic or disseminated disease call for 
antifungal therapy, but the choice of drugs, route, and 
duration of therapy is highly dependent on the form of the 
disease, the severity and site(s) of infection, and the immune 
status of the patient. Galgiani and colleagues have published 
clinical practice guidelines on the choice of drug and 
duration of therapy for a given form of the disease [18].
There are only two classes of antifungal therapy routinely 
used for treatment of coccidioidomycosis. The ﬁ  rst class is the 
polyenes, with amphotericin B desoxycholate and the newer 
lipid formulations used for the more serious forms of disease. 
The second class is the azoles, with ketoconazole, ﬂ  uconazole, 
itraconazole, and the newer analogue voriconazole as 
available options. Voriconazole, in particular, is being used 
more and more often in life-threatening mycoses, and was 
found to be better than amphotericin B in the primary 
therapy of invasive aspergillosis [19]. According to available 
reports, treatment in Latin America usually consists of one of 
the azoles (ﬂ  uconazole or itraconazole) and/or amphotericin 
B desoxycholate; lipid formulations are too costly to be 
accessible[20]. 
Treatment of the more serious or aggressive forms of the 
disease is typically of long duration and often results in less 
than complete resolution of disease; relapse is common 
[21]. Unfortunately, information on the treatment of 
coccidioidomycosis is limited, due to the small numbers of 
controlled trials performed for what is perceived to be a niche 
market. Clearly, newer, more powerful drugs are needed. 
In addition to drugs, surgery is sometimes indicated to 
remove focalized infections, such as pulmonary cavities, or to 
debride osseous forms of the disease [22].
Immunology and the Basis for a Vaccine
Acquired resistance to coccidioidomycosis strongly correlates 
with the development of a delayed-type hypersensitivity 
skin test response to coccidioidal antigens [23] and the 
production of T-helper-1 (Th1)-associated cytokines to 
coccidioidal antigens, such as interferon-gamma (IFN-γ) and 
Interleukin-2 (IL-2) [24]. Humoral immunity plays no known 
role in overcoming infection. 
Although all humans are equally susceptible to initial 
infection, there is evidence of genetic predisposition 
to dissemination, independent of socioeconomic or 
environmental factors, particularly among African-Americans 
and Filipinos [25]. Pregnancy is also a risk factor.
In cases of marked immunosuppression, either in advanced 
AIDS or other forms of depressed cellular immunity, the 
management of coccidioidomycosis is particularly challenging 
and requires aggressive treatment [26]. 
As previously mentioned, recovery from disease confers 
lifelong immunity to reinfection, and is a rationale for 
the development and implementation of a vaccine for 
the prevention of symptomatic or serious forms of the 
disease. The combination of increasing incidence of 
disease, a growing population in the endemic area, and 
the lack of a highly effective drug treatment justiﬁ  es efforts 
to prevent (rather than treat) this disease. To that end, 
a university-based consortium, the Valley Fever Vaccine 
Project (www.valleyfever.com), has identiﬁ  ed and cloned 
immunogenic proteins that have proven effective in the 
prevention of deaths and fungal burdens in mouse models 
of coccidioidomycosis. This suggests that a vaccine for use 
in humans could be created [27]. A candidate vaccine 
comprised of a fusion protein based on two antigens has been 
selected and is currently in pharmaceutical development 
under the sponsorship of this project, with the goal of 
evaluating the safety and immunogenicity in humans. 
Conclusion
Although the vast majority of infected individuals emerge 
from coccidioidomycosis without complications, an unlucky 
minority are faced with a debilitating disease that lacks 
adequate drug options for rapid and completely effective 
treatment. In the absence of newer therapeutics, discoveries 
that lead to immunologic intervention [28] or prevention by 
vaccines may ultimately bring a measure of relief.  
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